Longevity.TechnologyApr 22, 2026
Inflammation’s statin moment edges closer
BioAge's NLRP3 inhibitor BGE-102 produced marked reductions in inflammatory biomarkers (hsCRP, IL-6, fibrinogen) in Phase 1 testing, positioning upstream inflammasome inhibition as a potential scalable approach to chronic inflammation management. This advances a field that has lacked convenient, long-term preventive options despite growing evidence that inflammation drives cardiovascular and age-related disease.